In vivo molecular diagnostics in Alzheimer’s Disease (LeARN)
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2008
- Initiating Organization: Center for Translational Molecular Medicine (CTMM)
- Initiator Type: Government
- Disease focus:
Alzheimer's Disease - Location: Europe
Abstract
Mission
Age-related cognitive impairment and dementia impose an increasing burden on aging Western societies in terms of diminished quality-of-life and high healthcare costs (approximately €3 billion annually in the Netherlands). Memory loss is often regarded by patients as an indication that they may have Alzheimer’s Disease (AD), although in practice it is also a symptom of many far less serious conditions. An important challenge is therefore to differentiate those patients who will not develop dementia (who can thus be comforted) from those who will develop full-blown AD with dementia (for whom healthcare should be provided).
This project aims to develop new instruments with which to make an earlier and more reliable diagnosis of AD during life and create the conditions for an effective evaluation of novel medication therapies for AD patients.
These aims will be achieved by developing the following:
Consortium History
July 2008: Project began
Links/Social Media Feed
Other website |
Points of Contact
Principal Investigator
M. A. van Buchem
CTMM Program Manager
Henny Bruinewoud
Sponsors & Partners
BAC |
Cyclotron |
Leids Universitair Centrum |
Maastricht University Medical Center |
Merck-Sharpe & Dome |
Philips Electronics |
To-BBB |
Universitair Medisch Centrum St. Radbod |
Virtual Proteins |
VU Medisch Centrum |